Aurobindo Pharma Secures FTC Approval for Acquisition of Lannett Business
Aurobindo Pharma Ltd has announced that it has obtained the necessary approval from the US Federal Trade Commission (FTC) regarding the acquisition of the Lannett business by its subsidiary.The approval marks a significant milestone in the deal where Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, is set to acquire 100% of the membership interest in Lannett Company LLC. The transaction involves LANNETT SELLER HOLDCO, INC as the seller.
Aurobindo Pharma has stated that it anticipates the entire acquisition transaction will conclude before the end of the current month. The company plans to keep relevant parties informed regarding any future developments related to this matter.
AUROPHARMA Stock Price Movement
Aurobindo Pharma Limited rallied on Thursday, with shares edging up 1.66% to close at ₹1443.70 after a solid day of gains. The stock traded amid heavy interest, delivering 944,605 shares while briefly touching a high of ₹1447.7.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.